Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MiNK Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

MiNK Therapeutics şirketinin toplam hissedar öz sermayesi $-16.6M ve toplam borcu $4.4M olup, bu da borç-öz sermaye oranını -26.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.3M ve $26.9M dir.

Anahtar bilgiler

-26.6%

Borç/özkaynak oranı

US$4.41m

Borç

Faiz karşılama oranı	n/a
Nakit	US$9.31m
Eşitlik	-US$16.58m
Toplam yükümlülükler	US$26.90m
Toplam varlıklar	US$10.32m

Son finansal sağlık güncellemeleri

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Oct 26

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Jun 28

Recent updates

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Oct 26

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Jun 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: INKT negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: INKT şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: INKT negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: INKT 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: INKT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: INKT un, serbest nakit akışı her yıl % 7.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

MiNK Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

MiNK Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Value of Listed Securities

MiNK Therapeutics Provides Non-Compliance Update with the Nasdaq's Minimum Bid Price Requirement

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Therapeutics Receives Letter from Nasdaq Notifying the Company Failed to Comply with the $1 Minimum Bid Price

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Recent updates

Insufficient new directors

MiNK Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Value of Listed Securities

MiNK Therapeutics Provides Non-Compliance Update with the Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

New minor risk - Shareholder dilution

MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding

MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding

MiNK Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

MiNK Therapeutics, Inc. to Report Q4, 2023 Results on Mar 21, 2024

MiNK Therapeutics Receives Letter from Nasdaq Notifying the Company Failed to Comply with the $1 Minimum Bid Price

MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer

Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Mink’S Agent-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

MiNK Therapeutics, Inc. Announces Resignation of as Director

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Price target increased by 12% to US$7.00

Executive Chairman recently bought US$95k worth of stock

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Price target decreased to US$7.75

Mink Therapeutics, Inc. Presents Clinical Data At Sitc 2022 Showcasing Inkt Cell Therapy Pipeline

MiNK Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 2500 Value Index

MiNK Therapeutics A Bargain For Potential Cell Therapies

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

MiNK Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

MiNK Therapeutics, Inc. to Report Q4, 2021 Results on Mar 18, 2022

MiNK Therapeutics Announces Patients Dosed with Agent-797 iNKT Cell Therapy in Solid Tumor Cancers

High number of new directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin